The success of nanomedicine as a new strategy for drug delivery and targeting prompted the interest in developing approaches toward basic and clinical neuroscience. Despite enormous advances on brain research, central nervous system (CNS) disorders remain the world's leading cause of disability, in part due to the inability of the majority of drugs to reach the brain parenchyma. Many attempts to use nanomedicines as CNS drug delivery systems (DDS) were made; among the various non-invasive approaches, nanoparticulate carriers and, particularly, polymeric nanoparticles (NPs) seem to be the most interesting strategies. In particular, the ability of poly-lactide-co-glycolide NPs (PLGA-NPs) specifically engineered with a glycopeptide (g7), conferring to NPs' ability to cross the blood brain barrier (BBB) in rodents at a concentration of up to 10% of the injected dose, was demonstrated in previous studies using different routes of administrations. Most of the evidence on NP uptake mechanisms reported in the literature about intracellular pathways and processes of cell entry is based on in vitro studies. Therefore, beside the particular attention devoted to increasing the knowledge of the rate of in vivo BBB crossing of nanocarriers, the subsequent exocytosis in the brain compartments, their fate and trafficking in the brain surely represent major topics in this field.

Endocytosis of Nanomedicines: The Case of Glycopeptide Engineered PLGA Nanoparticles / Vilella, Antonietta; Ruozi, Barbara; Belletti, Daniela; Pederzoli, Francesca; Galliani, Marianna; Semeghini, Valentina; Forni, Flavio; Zoli, Michele; Vandelli, Maria Angela; Tosi, Giovanni. - In: PHARMACEUTICS. - ISSN 1999-4923. - ELETTRONICO. - 7:2(2015), pp. 74-89. [10.3390/pharmaceutics7020074]

Endocytosis of Nanomedicines: The Case of Glycopeptide Engineered PLGA Nanoparticles

VILELLA, ANTONIETTA;RUOZI, Barbara;BELLETTI, Daniela;PEDERZOLI, FRANCESCA;GALLIANI, MARIANNA;SEMEGHINI, VALENTINA;FORNI, Flavio;ZOLI, Michele;VANDELLI, Maria Angela;TOSI, Giovanni
2015

Abstract

The success of nanomedicine as a new strategy for drug delivery and targeting prompted the interest in developing approaches toward basic and clinical neuroscience. Despite enormous advances on brain research, central nervous system (CNS) disorders remain the world's leading cause of disability, in part due to the inability of the majority of drugs to reach the brain parenchyma. Many attempts to use nanomedicines as CNS drug delivery systems (DDS) were made; among the various non-invasive approaches, nanoparticulate carriers and, particularly, polymeric nanoparticles (NPs) seem to be the most interesting strategies. In particular, the ability of poly-lactide-co-glycolide NPs (PLGA-NPs) specifically engineered with a glycopeptide (g7), conferring to NPs' ability to cross the blood brain barrier (BBB) in rodents at a concentration of up to 10% of the injected dose, was demonstrated in previous studies using different routes of administrations. Most of the evidence on NP uptake mechanisms reported in the literature about intracellular pathways and processes of cell entry is based on in vitro studies. Therefore, beside the particular attention devoted to increasing the knowledge of the rate of in vivo BBB crossing of nanocarriers, the subsequent exocytosis in the brain compartments, their fate and trafficking in the brain surely represent major topics in this field.
7
2
74
89
Endocytosis of Nanomedicines: The Case of Glycopeptide Engineered PLGA Nanoparticles / Vilella, Antonietta; Ruozi, Barbara; Belletti, Daniela; Pederzoli, Francesca; Galliani, Marianna; Semeghini, Valentina; Forni, Flavio; Zoli, Michele; Vandelli, Maria Angela; Tosi, Giovanni. - In: PHARMACEUTICS. - ISSN 1999-4923. - ELETTRONICO. - 7:2(2015), pp. 74-89. [10.3390/pharmaceutics7020074]
Vilella, Antonietta; Ruozi, Barbara; Belletti, Daniela; Pederzoli, Francesca; Galliani, Marianna; Semeghini, Valentina; Forni, Flavio; Zoli, Michele; Vandelli, Maria Angela; Tosi, Giovanni
File in questo prodotto:
File Dimensione Formato  
pharmaceutics-82538-proofread_GT.pdf

non disponibili

Tipologia: Pre-print dell'autore (bozza pre referaggio)
Dimensione 406.82 kB
Formato Adobe PDF
406.82 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
1073435.pdf

accesso aperto

Tipologia: Versione dell'editore (versione pubblicata)
Dimensione 1.62 MB
Formato Adobe PDF
1.62 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/1073435
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 33
  • ???jsp.display-item.citation.isi??? 32
social impact